Pfizer Inc. (NYSE:PFE) is one of the stocks highlighted as Jim Cramer responded to questions from Harvard Business School students. A student asked if the stock, given the company’s reputation for innovation, its decline of over 50% from its peak, and recent deals involving Metsera and the Trump administration on drug pricing, is now a buy. In response, Cramer said: “No. Pfizer sells at eight times earnings and will continue to sell at eight times earnings. I’ll give you an example of what Dr. Bourla shou ...